The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial
Long-term cardiovascular complications following AKI
ERAKI & EuReCa-M Working Groups
Speaker
Ziad Massy, France
Panellists
Charles Ferro, United Kingdom
Francesca Mallamaci, Italy
Moderator
Jolanta Małyszko, Poland
Tuesday, March 25, 2025, at 5:00 PM (CET)